Finance
Pharmaceutical company reports first quarter 2005 results
Published in Vaccine Weekly, June 8th, 2005
Revenues for the quarter ended March 31, 2005, totaled $2.6 million compared to revenues of $1.7 million for the same period in 2004. Revenues primarily reflect funding from government grants and contracts and payments received by the company for contract work performed for our joint venture with Cytogen Corporation, the PSMA Development company LLC.
The company's expenses for the first quarter of 2005 were $15.9 million, compared to $12.2 million for the first quarter of 2004. The primary reason for the increase was additional spending...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-06-08)
More Articles from Vaccine Weekly
- Helicobacter Vaccine
Antibodies against Helicobacter pylori produced in egg yolks - Malaria Vaccine
Plasmodium berghei polypeptide plus adjuvant elicits immune response - Malaria Vaccine
Poxviruses enhance T cell-mediated protection against malaria - Respiratory Syncytial Virus
Fusion of DsbA to RSV epitope prolongs virus-specific CTL responses - Vaccine Vector
Human adenovirus type 11 developed as gene transfer vector - Acute Myeloid Leukemia
Dominant negative effects of AML1/ETO may be important for AML pathogenesis - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
